Abbott Laboratories Hits New 52-Week Low at USD 90.72

Abbott Laboratories has reached a new 52-week low, trading at USD 90.72 as of April 23, 2026. This significant decline reflects a challenging year for the company, which has seen its stock performance drop by 13.96% over the past year, contrasting sharply with the S&P 500's gain of 32.23%. Despite this downturn, Abbott Laboratories maintains a robust market position within the Pharmaceuticals and Biotechnology industry, boasting a market capitalization of USD 214.68 billion. The company has demonstrated a strong ability to manage its debt, evidenced by a low debt-to-equity ratio of 0.10 and a favorable debt-to-EBITDA ratio of 0.62 times. Abbott's operating profit has shown healthy growth, increasing at an annual rate of 13.45%. The company has also reported positive results for the last three consecutive quarters, with operating cash flow peaking at USD 9,037 million. While the stock is currently trading at a discount compared to its peers, it has generated a return of 8.01% over the past year, with profits rising by an impressive 140.3%.